Larimar Therapeutics, Inc. (LRMR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 3.83 |
| Open | 3.77 |
| Day High | 3.86 |
| Day Low | 3.72 |
| 52-Week High | 6.42 |
| 52-Week Low | 2.72 |
| Volume | 994,723 |
| Average Volume | 2.19M |
| Market Cap | 396.83M |
| PE | -1.85 |
| EPS | -2.06 |
| Moving Average 50 Days | 3.58 |
| Moving Average 200 Days | 3.9 |
| Change | -0.01 |
Larimar Therapeutics to Participate in Upcoming Investor Conferences in March
GlobeNewswire Inc.
Mar 04, 2026 9:05 PM GMT
BALA CYNWYD, Pa., March 04, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company
Larimar Therapeutics Announces Pricing of Upsized $100 Million Underwritten Public Offering
GlobeNewswire Inc.
Feb 26, 2026 1:59 AM GMT
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its upsized
Larimar Therapeutics Announces Proposed $75 Million Underwritten Public Offering
GlobeNewswire Inc.
Feb 25, 2026 9:01 PM GMT
BALA CYNWYD, Pa., Feb. 25, 2026 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an u